Gilead Sciences, Inc.
NEWS
Following AbbVie Lawsuit, Government Scrutinizes Industry-Provided Drug Educational Support Services
A federal investigation is underway into whether or not the nursing and other medical services provided by some pharmaceutical companies to doctor’s offices actually violate the law due to serving an illegal commercial service.
A paper entitled ‘Discovery of a Potent and Orally Bioavailable Cyclophilin Inhibitor Derived from the Sanglifehrin Macrocycle’ by authors from Selcia, Cypralis and Gilead has been selected as a featured article by the editors of The Journal of Medicinal Chemistry.
San Diego-based Viking Therapeutics announced positive top-line data from a 12-week Phase II clinical trial of VK2809 in non-alcoholic fatty liver disease (NAFLD) and elevated low-density lipoprotein cholesterol (LDL-C).
The Morgan Stanley Global Healthcare Conference ran from September 12 through 14, with numerous biopharma companies making presentations, updating their operations and pipeline activities. Here’s a look a few of the highlights.
Belgium-based Galapagos NV snagged $300 million following its U.S. public offering of new ordinary shares in the form of American Depositary Shares.
Gilead Sciences had a lot of news lately. First off, Gilead and Belgium-based Galapagos NV announced results from their FINCH 2 Phase III clinical trial of filgotinib in adults with moderately-to-severely active rheumatoid arthritis.
Gilead Sciences and its partner Galapagos NV announced results from its Phase II TORTUGA clinical trial of filgotinib, a selective JAK1 inhibitor, in adults with moderately to severely active ankylosing spondylitis (AS).
A number of companies are making the transition from the third quarter to the fourth quarter with licensing deals to bolster their pipelines. Here’s a look at just a few of them.
Biopharm companies closed out August with a plethora of changes to executive and senior leadership positions. Let’s take a look.
JOBS
IN THE PRESS